Biotech Hangout

Episode 77

Oct 25, 2023
Biotech analysts Jacob Plieth and Madeleine Armstrong, along with Nuvalent CEO Jim Porter, discuss Merck and Daichii's co-development deal, Nuvalent's $300M raise, and recent industry data. They also touch on the recent ESMO data breach, PTC Therapeutics' agreement with Royalty Pharma, and Revolution Medicines' KRAS data, among other topics.
Ask episode
Chapters
Transcript
Episode notes